A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

• Elritercept (Drug), also known as TAK-226: Elritercept, SC injection.
• Epoetin Alfa (Drug): Epoetin Alfa, SC injection.

Primary outcomes

• Proportion of Participants who are RBC Transfusion Independent (RBC-TI) for any Consecutive Greater Than Equal to (≥) 12-Week Period From Day 1 Through 24 Weeks With Concurrent Mean Hemoglobin (Hgb) Increase ≥ 1.5 Grams per Deciliter (g/dL) From Baseline [From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)]: RBC-TI is defined as no red blood cell (RBC) transfusions administered for the specified time period during study treatment.

Secondary outcomes

• Proportion of Participants who are RBC-TI for any Consecutive ≥16-Week Period From Day 1 to 24 Weeks [From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)]: RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
• Proportion of Participants who are RBC-TI for any Consecutive ≥12-Week Period From Day 1 to 24 Weeks [From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)]: RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
• Proportion of Participants who are RBC-TI for a Consecutive 24-Week Period From Day 1 [From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)]: RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
• Proportion of Participants Who Have Meaningful Improvement or Maintain a High Score With no Meaningful Deterioration in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score With no RBC Transfusions Based on the Average of Scores [From End of Week 12 to End of Week 24]: The FACT-An questionnaire is used to assess the effects of disease symptoms on functioning and well-being in participants with anemia. The FACT-An Anemia scale includes 13 fatigue-specific items (which together comprise the FACIT-Fatigue scale).
• Proportion of Participants who Achieved Hematological Improvement-Erythroid (HI-E) for a Minimum 8-Week Period From Day 1 to 24 Weeks [From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)]: HI-E is defined as percentage of participants meeting HI-E criteria sustained over any consecutive 56-day period over the first 24 weeks.
• Proportion of Participants who Achieved Hematological Improvement-Erythroid (HI-E) for a Minimum 12-Week Period From Day 1 to 48 Weeks [From Cycle 1 Day 1 through Week 48 (each cycle is 28 days)]: HI-E is defined as percentage of participants meeting HI-E criteria sustained over any consecutive 84-day period over the 48 weeks.
• Proportion of Participants who are RBC-TI for a Minimum Consecutive 8-Week Period From Day 1 to 24 Weeks [From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)]
• Proportion of Participants who are RBC-TI for a Minimum Consecutive 24-Week Period From Day 1 to 48 Weeks [From Cycle 1 Day 1 through Week 48 (each cycle is 28 days)]
• Time From Date of First Dose to First Onset of Achieving RBC-TI [From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)]: RBC-TI is defined as the absence of RBC transfusions for a prespecified period of time during continued treatment. Time from date of first dose to first onset of achieving RBC-TI for minimum consecutive 12 weeks and for minimum consecutive 16 weeks.
• Mean Hgb Change From Baseline Through 24 Weeks and 48 Weeks [From Baseline through Week 24 and Week 48]
• Maximum Duration of RBC-TI for Participants who Achieved RBC-TI for a Consecutive ≥12 Weeks and ≥16 Weeks [From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)]
• Total Number of Packed Red Blood Cells (pRBC) Units Received During the Study Treatment [From Cycle 1 Day 1 to End of Treatment (approximately 5 years) (each cycle is 28 days)]
• Monthly Average of pRBC Units Received During Study Treatment Period [From Cycle 1 Day 1 to End of Treatment (approximately 5 years) (each cycle is 28 days)]
• Time From Date of First Dose of Study Drug to Date of First RBC Transfusion Received During Treatment Period [From Cycle 1 Day 1 to End of Treatment (approximately 5 years) (each cycle is 28 days)]
• Time From Date of First Dose of Study Drug to First Onset of Achieving HI-E for Minimum Consecutive 8 Weeks Period [From Cycle 1 Day 1 through Week 24 (each cycle is 28 days)]
• Proportion of Participants with Meaningful Improvement in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Scale Scores [From Cycle 1 Day 1 through Week 24 and 48 (each cycle is 28 days)]: EORTC QLQ-C30 is a 30-item,participant-reported multidomain questionnaire designed to assess the functioning,well-being,and symptom experience of patients with cancer.
• Proportion of Participants with Meaningful Improvement in FACT-Anemia (FACT-An) Scale Scores [From Cycle 1 Day 1 through Week 24 and 48 (each cycle is 28 days)]: The FACT-An questionnaire is used to assess the effects of disease symptoms on functioning and well-being in participants with anemia.
• Proportion of Participants with Meaningful Improvement in FACIT-Fatigue Scale Scores [From Cycle 1 Day 1 through Week 24 and 48 (each cycle is 28 days)]: The FACT-An Anemia scale includes 13 fatigue-specific items (which together comprise the FACIT-Fatigue scale).
• Time to Confirmed Improvement and Time to Confirmed Deterioration in EORTC QLQ-C30 Scale Scores [Baseline through Week 24 and 48]: EORTC QLQ-C30 is a 30-item,participant-reported multidomain questionnaire designed to assess the functioning,well-being,and symptom experience of patients with cancer.
• Time to Confirmed Improvement and Time to Confirmed Deterioration in FACT-An Scale Scores [Baseline through Week 24 and 48]: The FACT-An questionnaire is used to assess the effects of disease symptoms on functioning and well-being in participants with anemia.
• Time to Confirmed Improvement and Time to Confirmed Deterioration in FACIT-Fatigue Scale Scores [Baseline through Week 24 and 48]: The FACT-An Anemia scale includes 13 fatigue-specific items (which together comprise the FACIT-Fatigue scale).
• Average Changes in EORTC QLQ-C 30 Scale Scores Through 48 Weeks [Up to Week 48]: EORTC QLQ-C30 is a 30-item,participant-reported multidomain questionnaire designed to assess the functioning,well-being,and symptom experience of patients with cancer.
• Average Changes in FACT-An Scale Scores Through 48 Weeks [Up to Week 48]: The FACT-An questionnaire is used to assess the effects of disease symptoms on functioning and well-being in participants with anemia.
• Average Changes in FACIT-Fatigue Scale Scores Through 48 Weeks [Up to Week 48]: The FACT-An Anemia scale includes 13 fatigue-specific items (which together comprise the FACIT-Fatigue scale).
• Concentration of Study Drug in Plasma Over Time Data for Participants Treated With Elritercept [Pre-dose and multiple times post-dose from Cycle 1 Day 1 up to Cycle 13 Day 1 (approximately 49 weeks) (each cycle is 28 days)]
• Proportion of Participants Treated with Elritercept with Antidrug Antibodies (ADA) [From Cycle 1 Day 1 to 60 days post last dose (approximately 5 years) (each cycle is 28 days)]
• Time from Randomization to First Diagnosis of Acute Myeloid Leukemia (AML) [From Randomization to Week 48]: Progression of disease to diagnosis of AML as per world health organisation (WHO) classification of ≥20 percent (%) blasts in peripheral blood or bone.
• Time From Randomization to the Death of a Participant From any Cause [From Randomization to Week 48]

Sex: All, ages: 18 Years to any

Inclusion Criteria

1. Male or female participants aged ≥ 18 years or older at time of signing the informed consent form (ICF).
2. Able to understand the purpose and risks of the trial and voluntarily sign an ICF prior to any trial-related procedures being conducted and authorization to use protected health information and personal data in accordance to national and local privacy regulations.
3. Documented diagnosis of myelodysplastic syndrome(s) (MDS) according to WHO 2016 classification that meets International Prognostic Scoring System - Revised (IPSS-R) classification of very low-, low-, or intermediate-risk disease, confirmed by central laboratory independent reviewer prior to randomization. Hemoglobin (HgB), platelet, and absolute neutrophil count (ANC) values should be collected greater than (>) 14 days after red blood cell (RBC) transfusion or > 7 days after platelet transfusion, unless otherwise considered to be pretransfusion values.
4. Bone marrow less than (<) 5% blasts in an evaluable bone marrow collected at screening and confirmed by central pathology independent reviewer.
5. Endogenous serum erythropoietin (EPO) level of <500 units per liter (U/L). Should be results from blood samples collected >14 days following an RBC transfusion to evaluate for eligibility unless considered pretransfusion values.
6. Participant requires RBC transfusion, as documented by the following criteria. A transfusion requirement of 2 to 6 pRBCs units/8 weeks confirmed for a minimum of 8 weeks immediately preceding randomization.

   * Hgb levels at the time of or within 3 days prior to administration of a RBC transfusion must have been less than or equal to (≤) 9.0 grams per deciliter (g/dL) (5.6 millimoles per liter (mmol/L)) with symptoms of anemia (or ≤7 g/dL \[4.3 mmol/L\] in the absence of symptoms) in order for the transfusion to be counted towards meeting eligibility criteria.
   * RBC transfusions administered when hemoglobin (Hgb) levels were >9.0 g/dL (or >7 g/dL in the absence of symptoms) and/or RBC transfusions administered for elective surgery, infections or bleeding events will not qualify as a required transfusion for the purpose of meeting eligibility criteria or stratification.
7. Hgb <11.0 g/dL (6.8 mmol/L) before randomization. Local laboratory is acceptable to facilitate randomization.
8. Eastern Cooperative Oncology Group score of 0, 1, or 2.

Exclusion Criteria

1. Prior therapy with any of the following:

   1. Epoetin alfa

      • At the investigator's discretion in consultation with the medical monitor, may be allowed if received no more than 2 doses of only epoetin alfa ≥8 weeks prior to randomization.
   2. Darbepoetin

      • At the investigator's discretion in consultation with the medical monitor, may be allowed if received no more than 1 dose of only darbepoetin ≥8 weeks prior to randomization.
   3. Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor administered ≤8 weeks (56 days) prior to randomization unless given for treatment of febrile neutropenia.
   4. Immunomodulatory drug (IMiDs) including lenalidomide

      • At the investigator's discretion in consultation with the medical monitor may be allowed if received ≤1 week of an IMiD ≥8 weeks prior to randomization.
   5. Hypomethylating agent

      • At the investigator's discretion, in consultation with the medical monitor may be allowed if received no more than 2 doses ≥8 weeks prior to randomization.
   6. Luspatercept, sotatercept, imetelstat, or elritercept
   7. Immunosuppressive therapy for the disease under study.
   8. Hematopoeitic cell transplant
   9. Iron chelation if initiated ≤8 weeks prior to randomization. Participants on stable or decreasing doses of iron chelation therapy for ≥8 weeks are allowed.
   10. Vitamin B12 or folate therapy initiated within 4 weeks prior to randomization. Participants on stable or decreasing replacement doses for ≥4 weeks and without ongoing concurrent vitamin B12 or folate deficiency are allowed.
   11. Androgen use within 8 weeks before randomization. Participants on stable androgen dosing for hypogonadism for ≥8 weeks are allowed
   12. High-dose systemic corticosteroid use within 4 weeks before randomization. Participants on stable chronic steroid doses of prednisone ≤10 millligrams per day (mg/day) or corticosteroid equivalent for ≥4 weeks are allowed. Other disease modifying treatments for autoimmune diseases may be allowed upon medical monitor review.
   13. Investigational agent or any other agent intended for MDS treatment
2. Diagnosed to have MDS with presence of del(5q) cytogenetic abnormality or MDS unclassifiable according to WHO 2016 classification or secondary MDS.
3. Known history of diagnosis of acute myeloid leukemia (AML).
4. Anemia due to any other known cause including but not limited to thalassemia; hypothyroidism, autoimmune or hereditary hemolytic anemia, any type of known clinically significant bleeding or sequestration or drug induced anemia, hemolytic anemia, bleeding events, or other deficiencies (that is, iron, folate, or vitamin B12).
5. Clinically significant cardiovascular disease defined as:

   1. New York Heart Association heart disease class III or IV
   2. Fridericia corrected QT (QTcF) interval >500 milliseconds during screening
   3. Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before screening
6. Known ejection fraction <35%, confirmed by a local echocardiogram performed during screening, or a previously performed echocardiogram if collected within 6 months before screening.
7. Medical history of thromboembolic events within 6 months before screening, including history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (DVT; including proximal and distal), pulmonary or arterial embolism, arterial thrombosis or other venous thrombosis. Participants with prior superficial thrombophlebitis are allowed.
8. Uncontrolled hypertension, defined as repeated elevations of systolic blood pressure of ≥160 millimeters of mercury (mmHg) and/or diastolic blood pressure ≥100 mmHg despite adequate treatment.
9. Prior history of malignancies, other than MDS. Participants who are free of other malignant disease for ≥3 years and have completed treatment, including maintenance are allowed. Participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy:

   1. Basal or squamous cell carcinoma of the skin;
   2. Carcinoma in situ of the cervix;
   3. Carcinoma in situ of the breast;
   4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis \[TNM\] or early papillary thyroid cancer (Stage I \[T1-T2, N0, M0\]) clinical staging system).
10. History of solid organ or bone marrow transplantation.
11. Active infection requiring intravenous antibiotics within 28 days or oral antibiotics within 14 days before randomization.
12. Known positive for human immunodeficiency virus (HIV), active infectious hepatitis B virus (HBV), or active infectious hepatitis C virus (HCV). Participants without known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines.
13. Body mass index ≥ 40 kilograms per square meter (kg/m\^2).
14. Major surgery within 28 days before randomization.
15. New-onset seizures or poorly controlled seizures within 12 weeks prior to randomization are excluded from trial participation.
16. History of allergy/anaphylaxis to investigational product (including epoetin alfa) excipients (refer to the current elritercept investigator's brochure for a list of excipients) or recombination proteins.
17. History of pure red cell aplasia and/or antibody against erythropoietin (EPO).
18. Any of the following laboratory abnormalities:

    1. ANC <500/microliter (μL) (0.5×10\^9/liter \[L\]).
    2. Platelet count <50,000/μL (50×10\^9/L) or ≥800,000/μL (800×10\^9/L).
    3. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3× upper limit of the normal (ULN).
    4. Total bilirubin ≥2×ULN. Participants with known history of Gilbert syndrome with unconjugated bilirubin <3×ULN are allowed. Higher levels if attributed to active RBC precursor destruction within the bone marrow (ineffective erythropoiesis) may be allowed upon medical monitor review.
    5. Estimated glomerular filtration rate <30 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2) as determined by the Chronic Kidney Disease Epidemiology (CKD-EPI) collaboration equation.
    6. Ferritin ≤50 micrograms per liter (μg/L).
    7. Folate ≤2.0 nanograms per milliliter (ng/mL).
    8. Vitamin B12 ≤200 picograms per milliliter (pg/mL).
19. Ongoing participation in another interventional clinical trial or use of any other investigational medicinal product within 5 times the half-life.
20. Participant is unwilling or in the opinion of the investigator the participant is unable to comply with the requirements of the protocol.
21. Is a participant of childbearing potential (POCBP) but does not agree to use at least 1 form of highly effective contraception from the time of signing the ICF until at least 60 days after the last dose of trial intervention.
22. Participants of male birth who are fertile and who have partners of childbearing potential, who do not agree to use acceptable barrier contraception, that is, a male condom during the entire trial intervention period until at least 60 days after the last dose of trial intervention.
23. If applicable, participant with a positive serum pregnancy test during the screening period or known to be pregnant or a lactating participant who does not agree to forego breastfeeding during the entire trial intervention period until at least 60 days after the last dose of trial intervention.
24. For Participants in France: Persons under court protection, persons not affiliated with a social security system, and protected adults.

62 more sites not listed.

• Study Director, Study director, Takeda

NIH grants: 2025